BioSig Resumes Clinical Activities with PURE EP System

Ken Londoner, Chairman and CEO of BioSig Technologies, has recently announced company’s plans to resume its clinical activities with patient cases at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX.

Ken Londoner has also shared that BioSig Technologies is actively negotiating with a number of other centers in order to continue its clinical activities and to initiate new installations of its PURE EP(tm) System.

Londoner claims that the return of BioSig Technologies to supporting cases, represents an important step for the company. BioSig’s team has positioned itself for a strong transition back.

Londoner indicates that over the past two months, a tremendous amount of clinical data was analyzed, training were conducted and a number of important physician engagement activities were initiated by BioSig’s team. Londoner looks forward to bring the PURE signals to more patients and physicians

Londoner indicated that the COVID-19 pandemic has profoundly impacted patients with cardiac arrhythmias.

“Due to cancellation or postponement of elective procedures, their already debilitating conditions were likely to worsen,” says Londoner.

The executive sincerely appreciates their physician collaborators’s commitment who, during these challenging times, continued to put patient needs first. Londoner and its teal are grateful to help the hospitals care for their patients.

BioSig’s first clinical trial was initiated in November 2019. Currently, patients at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center and Mayo Clinic’s Florida campus are enrolled in this trial.

Observational patient cases at Indiana University School of Medicine, Santa Barbara Cottage Hospital, Greenville Memorial Hospital, and Texas Cardiac Arrhythmia Institute at St. David’s Medical Center were conducted earlier in 2019 by BioSig.

The  PURE EP(tm) System, BioSig’s first product, was used in over 120 procedures on patients suffering from different types of complex arrhythmias.

BioSig’s commitment to expanding its clinical footprint and seeking to commercialize its system, were stated in the recent Shareholder Letter of the company.